

Jorge Aparicio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/252006/publications.pdf>

Version: 2024-02-01

46
papers

2,536
citations

279701

23
h-index

243529

44
g-index

48
all docs

48
docs citations

48
times ranked

2286
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. <i>Annals of Oncology</i> , 2015, 26, 1722-1728.	0.6	271
2	Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapyâ€”Results From an International Study Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2647-2657.	0.8	264
3	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, 1658-1686.	0.6	228
4	Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 8717-8723.	0.8	202
5	Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5416-5421.	0.8	117
6	Clinical Pattern and Therapeutic Results Achieved in 1490 Patients with Germ-Cell Tumours of the Testis: the Experience of the Spanish Germ-Cell Cancer Group (GC). <i>European Urology</i> , 2002, 42, 553-563.	0.9	115
7	Multicenter study evaluating a dual policy of postorchectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. <i>Annals of Oncology</i> , 2003, 14, 867-872.	0.6	115
8	Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4677-4681.	0.8	113
9	Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). <i>Annals of Oncology</i> , 2014, 25, 2173-2178.	0.6	103
10	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Optionsâ€”An Analysis From the Global Germ Cell Cancer Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 345-351.	0.8	69
11	Preoperative Chemotherapy in Patients With Intermediate-Risk Rectal Adenocarcinoma Selected by High-Resolution Magnetic Resonance Imaging: The GEMCAD 0801 Phase II Multicenter Trial. <i>Oncologist</i> , 2014, 19, 1042-1043.	1.9	66
12	Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. <i>Annals of Oncology</i> , 2015, 26, 833-838.	0.6	57
13	Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. <i>Annals of Oncology</i> , 2005, 16, 1915-1920.	0.6	55
14	Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 194-200.	0.8	41
15	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 46-54.	1.2	40
16	Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3889.	1.0	35
17	E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification: The Spanish Germ Cell Cancer Group experience. <i>Annals of Oncology</i> , 2001, 12, 487-491.	0.6	31
18	FOLFOX Alternated with FOLFIRI as First-Line Chemotherapy for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, 263-267.	1.0	30

#	ARTICLE	IF	CITATIONS
19	First-line bevacizumab and capecitabine+oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. <i>British Journal of Cancer</i> , 2014, 111, 241-248.	2.9	29
20	Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. <i>European Journal of Cancer</i> , 2002, 38, 1204-1211.	1.3	28
21	SEOM clinical guidelines in gestational trophoblastic disease (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 38-46.	1.2	28
22	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 972-981.	1.2	26
23	Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1322-1331.	0.8	23
24	Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. <i>Annals of Oncology</i> , 2003, 14, 1121-1125.	0.6	19
25	Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base. <i>Clinical and Translational Oncology</i> , 2014, 16, 959-965.	1.2	16
26	SEOM clinical guidelines for the management of germ cell testicular cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1187-1196.	1.2	16
27	Recommendations for follow-up of colorectal cancer survivors. <i>Clinical and Translational Oncology</i> , 2019, 21, 1302-1311.	1.2	15
28	SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010). <i>Clinical and Translational Oncology</i> , 2011, 13, 560-564.	1.2	13
29	A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study. <i>Oncology</i> , 2018, 95, 8-12.	0.9	12
30	First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer. <i>Oncology</i> , 2005, 68, 58-63.	0.9	11
31	SEOM Clinical Guideline of localized rectal cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1163-1171.	1.2	10
32	Management options for stage I seminoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1077-1085.	1.1	9
33	Multicenter Phase I Study of Irinotecan plus Raltitrexed in Patients with 5-Fluorouracil-Refractory Advanced Colorectal Cancer. <i>Oncology</i> , 2002, 63, 42-47.	0.9	7
34	SEOM clinical guidelines to primary prevention of cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 106-113.	1.2	7
35	Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. <i>Cancers</i> , 2020, 12, 2259.	1.7	6
36	The Sword of Damocles and the Treatment of Stage I Seminoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 2599-2600.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Positron emission tomography (PET) is not indicated in the postchemotherapy evaluation of advanced non-seminomatous testicular germ cell tumors. <i>Clinical and Translational Oncology</i> , 2014, 16, 509-510.	1.2	5
38	Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. <i>Clinical and Translational Oncology</i> , 2021, 23, 58-64.	1.2	5
39	Myths and Facts on Adjuvant Carboplatin for Stage I Seminoma. <i>Journal of Clinical Oncology</i> , 2006, 24, e40-e40.	0.8	4
40	Treatment of Stage I Testicular Germ-Cell Tumors. <i>Medical Oncology</i> , 2006, 23, 305-316.	1.2	2
41	Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. <i>European Urology Focus</i> , 2017, 3, 280-286.	1.6	2
42	Prognostic factors for relapse in stage I testicular seminoma: tumor size and rete testis invasion revisited. <i>Clinical and Translational Oncology</i> , 2018, 20, 1358-1359.	1.2	2
43	Re: Mette SaksÅ, Mortensen, Jakob Lauritsen, Maria Gry Gundgaard, et al. A Nationwide Cohort Study of Stage I Seminoma Patients Followed on a Surveillance Program. <i>Eur Urol</i> 2014;66:1172â€“8. <i>European Urology</i> , 2015, 67, e93-e94.	0.9	1
44	Controversies in the management of stage I seminoma: adjuvant carboplatin revisited. <i>Clinical and Translational Oncology</i> , 2019, 21, 246-247.	1.2	1
45	Reply to F. Herrera et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2022-2022.	0.8	0
46	Avances recientes en el tratamiento de tumores de c�lulas germinales no seminomatosos en estadio i. <i>Actas Urol�gicas Espa�olas</i> , 2021, 45, 326-327.	0.3	0